Breakthroughs in research and drug therapies have the potential to improve human health around the world. With no shortage of consumer health concerns - let alone a pandemic like COVID-19 - there is a rising urgency for the life sciences industry to respond. Scaling biotech companies - which, together with small companies, have been responsible for bringing 63 percent of new products to market since 20131 - are feeling the pressure like never before. Capital investment funding was at an all-time high prior to COVID-19, but with it comes increased expectations for more innovative discoveries and quicker times to market. Being less stifled with bureaucracy than their larger counterparts, scaling life sciences companies may have a built-in advantage in their ability to respond quickly to market changes and opportunities. But with the growing demand for ever-faster discoveries and approvals and a new normal following COVID-19, now is the time for innovative thinking to leverage that strength even more. Reimagining commercial real estate can lead to gamechanging strategies. In this short question and answer (Q&A) session, we’ll identify areas where real estate and infrastructure can improve efficiencies, increase innovation, and positively impact success.